Etidronsaeure en es it fr

Etidronsaeure Brand names, Etidronsaeure Analogs

Etidronsaeure Brand Names Mixture

  • No information avaliable

Etidronsaeure Chemical_Formula


Etidronsaeure RX_link

Etidronsaeure fda sheet

Etidronsaeure msds (material safety sheet)

Etidronsaeure Synthesis Reference

No information avaliable

Etidronsaeure Molecular Weight

391.46 g/mol

Etidronsaeure Melting Point

No information avaliable

Etidronsaeure H2O Solubility

10 mg/L

Etidronsaeure State


Etidronsaeure LogP


Etidronsaeure Dosage Forms

Tablets (100 mg)

Etidronsaeure Indication

For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.

Etidronsaeure Pharmacology

Flavoxate is a spasmolytic flavone derivative that acts by relaxing the smooth muscle in the urinary tract. Flavoxate is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Muscarinic receptors play an important role in several major cholin-ergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion.

Etidronsaeure Absorption

Well absorbed from gastrointestinal tract.

Etidronsaeure side effects and Toxicity

The oral LD50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD50 for flavoxate HCl in mice is 1837 mg/kg. Symptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.

Etidronsaeure Patient Information

Etidronsaeure Organisms Affected

Humans and other mammals